Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 05 02:42PM ET
111.10
Dollar change
+1.69
Percentage change
1.54
%
Index- P/E19.85 EPS (ttm)5.60 Insider Own3.45% Shs Outstand62.26M Perf Week-0.72%
Market Cap6.86B Forward P/E5.16 EPS next Y21.53 Insider Trans-0.31% Shs Float59.62M Perf Month2.38%
Income394.92M PEG1.59 EPS next Q5.50 Inst Own95.37% Short Float5.86% Perf Quarter-1.02%
Sales3.91B P/S1.75 EPS this Y6.64% Inst Trans-0.74% Short Ratio5.56 Perf Half Y-0.10%
Book/sh60.94 P/B1.82 EPS next Y10.38% ROA3.49% Short Interest3.49M Perf Year-15.87%
Cash/sh32.08 P/C3.46 EPS next 5Y12.49% ROE10.84% 52W Range99.06 - 134.48 Perf YTD-9.67%
Dividend Est.- P/FCF6.57 EPS past 5Y-3.53% ROI4.42% 52W High-17.39% Beta0.55
Dividend TTM- Quick Ratio1.90 Sales past 5Y15.52% Gross Margin73.60% 52W Low12.15% ATR (14)2.53
Dividend Ex-Date- Current Ratio2.25 EPS Y/Y TTM546.69% Oper. Margin16.63% RSI (14)50.38 Volatility1.78% 2.20%
Employees2800 Debt/Eq1.54 Sales Y/Y TTM3.91% Profit Margin10.10% Recom1.50 Target Price175.72
Option/ShortYes / Yes LT Debt/Eq1.37 EPS Q/Q70.48% Payout0.00% Rel Volume0.72 Prev Close109.41
Sales Surprise1.37% EPS Surprise7.68% Sales Q/Q6.95% EarningsNov 06 AMC Avg Volume627.52K Price111.10
SMA20-0.36% SMA500.56% SMA200-1.66% Trades Volume366,851 Change1.54%
Date Action Analyst Rating Change Price Target Change
Jun-05-24Initiated Goldman Buy $169
Jan-03-24Initiated Robert W. Baird Outperform $160
Nov-27-23Downgrade UBS Buy → Neutral $170 → $135
Sep-29-23Initiated Raymond James Mkt Perform
Jun-12-23Resumed Wells Fargo Equal Weight $184 → $140
Dec-09-22Upgrade Goldman Neutral → Buy $192 → $190
Jun-14-22Initiated UBS Buy $194
Apr-06-22Downgrade Goldman Buy → Neutral $202 → $196
Nov-19-21Resumed Goldman Buy $198
Oct-07-21Resumed Jefferies Buy $172
Nov-04-24 09:16AM
Oct-31-24 04:05PM
Oct-30-24 10:01AM
Oct-27-24 02:00AM
Oct-24-24 08:30AM
04:15PM Loading…
Oct-23-24 04:15PM
Oct-18-24 04:34PM
05:21AM
Oct-17-24 09:55AM
09:40AM
Oct-16-24 03:55PM
08:54AM
07:35AM
Oct-15-24 11:50AM
10:31AM
07:30AM Loading…
07:30AM
06:47AM
Oct-14-24 09:52AM
Oct-11-24 12:32PM
Oct-09-24 04:15PM
Oct-08-24 04:22AM
Oct-04-24 10:00AM
Oct-03-24 07:40AM
Oct-01-24 09:40AM
Sep-16-24 07:30AM
Sep-09-24 07:58AM
Sep-07-24 10:17PM
Sep-05-24 07:30AM
01:07AM
Sep-04-24 12:12AM
07:00AM Loading…
Sep-03-24 07:00AM
Sep-02-24 06:05PM
Aug-30-24 11:31AM
01:16AM
Aug-23-24 10:13AM
Aug-22-24 04:05PM
Aug-21-24 04:15PM
Aug-06-24 09:55AM
09:40AM
Aug-05-24 04:06PM
09:15AM
Jul-31-24 10:36PM
05:45PM
04:40PM
04:05PM
Jul-29-24 06:00AM
Jul-25-24 04:05PM
Jul-24-24 10:01AM
Jul-23-24 03:52AM
Jul-22-24 07:45AM
Jul-19-24 01:58PM
Jul-17-24 04:15PM
Jul-11-24 08:30AM
Jul-09-24 07:45AM
Jul-04-24 08:09AM
Jul-01-24 12:16AM
Jun-26-24 02:11PM
Jun-25-24 03:39PM
Jun-21-24 07:00AM
06:33AM
Jun-20-24 04:08PM
10:08AM
07:45AM
Jun-14-24 06:13AM
Jun-11-24 10:42AM
Jun-03-24 02:27PM
Jun-01-24 08:05AM
May-31-24 11:31AM
May-30-24 07:30AM
May-29-24 04:15PM
07:45AM
May-28-24 07:00AM
May-26-24 10:09AM
May-23-24 06:00AM
May-22-24 07:01PM
04:00PM
May-17-24 02:32PM
May-09-24 09:19AM
May-08-24 04:30PM
01:22PM
May-07-24 05:37PM
10:57AM
May-06-24 09:29AM
May-03-24 12:41PM
11:49AM
May-02-24 11:26AM
03:53AM
May-01-24 08:56PM
07:00PM
04:24PM
04:10PM
04:05PM
Apr-30-24 09:50AM
Apr-24-24 04:05PM
10:01AM
05:21AM
Apr-23-24 11:15AM
Apr-17-24 04:15PM
Apr-10-24 07:45AM
Apr-04-24 09:15AM
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COZADD BRUCE COfficerNov 01 '24Proposed Sale110.841,000110,840Nov 01 03:19 PM
Henderson Mary ElizabethSVP, Technical OperationsSep 06 '24Sale108.301,410152,70314,531Sep 11 11:38 AM
Henderson Mary ElizabethOfficerSep 06 '24Proposed Sale110.002,691296,010Sep 05 07:50 PM
Winningham Rick EDirectorAug 06 '24Proposed Sale111.003,075341,325Aug 05 09:57 PM
Smith Mark DouglasDirectorAug 06 '24Proposed Sale111.003,075341,325Aug 05 09:55 PM
RIEDEL NORBERT GDirectorAug 06 '24Proposed Sale111.003,075341,325Aug 05 09:49 PM
ORiordan AnneDirectorAug 06 '24Proposed Sale111.003,075341,325Aug 05 09:42 PM
O'Keefe Kenneth WDirectorAug 06 '24Proposed Sale111.003,075341,325Aug 05 09:35 PM
McSharry Heather AnnDirectorAug 06 '24Proposed Sale111.003,075341,325Aug 05 09:29 PM
Cook Jennifer E.DirectorAug 06 '24Proposed Sale111.003,075341,325Aug 05 09:19 PM
Sohn Catherine A.DirectorAug 05 '24Proposed Sale111.003,075341,325Aug 02 04:20 PM
Carr PatriciaSVP, Chief Accounting OfficerJun 07 '24Sale108.8316317,7386,596Jun 11 08:15 PM
Patil Neena MEVP & Chief Legal OfficerMay 03 '24Sale109.655,000548,25036,629May 07 05:31 PM
Carr PatriciaSVP, Chief Accounting OfficerMar 06 '24Sale119.641,936231,6288,364Mar 08 06:07 PM
Carr PatriciaSVP, Chief Accounting OfficerMar 07 '24Sale116.981,768206,8216,596Mar 08 06:07 PM
Johnson Philip LEVP & Chief Financial OfficerMar 01 '24Buy119.6512,0001,435,80027,932Mar 05 07:28 PM
Smith Mark DouglasDirectorDec 04 '23Sale119.2741749,7366,888Dec 06 04:39 PM
Cook Jennifer E.DirectorDec 04 '23Sale119.2741749,7366,888Dec 06 04:31 PM